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Objective As patients with multiple sclerosis (MS) have
more than 2.5-fold increased mortality risk, we sought
to investigate the impact of tobacco smoking on the risk
of premature death and its contribution to the excess
mortality in MS patients.
Methods We studied 1032 patients during the period
1994–2013 in a UK-based register. Cox regression
model was used to investigate the impact of smoking on
the risk of premature death, controlling for confounders.
Smoking-speciﬁc mortality rates were compared with the
UK general population.
Results Of 923 patients with clinically deﬁnite MS, 80
(46 males and 34 females) had died by December 2012.
HRs for death in current smokers and ex-smokers relative
to never smokers were 2.70 (95% CI 1.59 to 4.58,
p<0.001) and 1.30 (95% CI 0.72 to 2.32; p = 0.37).
The standardised mortality ratio, compared with the UK
general population, when stratiﬁed by smoking status
was 3.83 (95% CI 2.71 to 5.42) in current smokers,
1.96 (95% CI 1.27 to 3.0) in ex-smokers and 1.27
(95% CI 0.87 to 1.86) in non-smokers. Never smokers
and ex-smokers with MS had similar mortality rates
compared with never smokers and ex-smokers without
MS in the male British doctors cohort (1.12 (95% CI
0.63 to 1.97) and 0.54 (95% CI 0.26 to 1.14),
respectively), while current smokers with MS had 84%
higher rate of death compared with current smokers
without MS (95% CI 1.24 to 2.72).
Conclusions Tobacco smoking can account for some
of the excess mortality associated with MS and is a risk
determinant for all-cause and MS-related death.
INTRODUCTION
Multiple sclerosis (MS) is associated with a range
of largely irreversible and progressive disability but
is not considered a lethal disease. Life span in
patients with MS is estimated to be 5–10 years
shorter than in the general population.1–3
Mortality is a major health outcome, which is often
ignored in the studies of neurological conditions
such as MS,4 possibly due to the long duration of
follow-up required. As a result, there is little infor-
mation about the non-demographic risk factors
associated with increased mortality rates. A range
of lifestyle, environmental risk factors, demo-
graphic characteristics and healthcare interventions
inﬂuence mortality. Among the lifestyle factors,
tobacco smoking is the most prominent preventable
cause of premature death,5 being associated with a
signiﬁcant decrease in life expectancy,6 7 and has
previously been linked to more severe disease in
MS patients.8–11 Tobacco smoking is a complex
factor in the aetiology and progression of neuro-
logical conditions. While tobacco smoking has been
shown to reduce the risk of mortality in patients
with PD,12 its effect on the risk of mortality in MS
patients is not clear. Higher prevalence of smoking
in MS populations13 may explain, in part, the
reported shorter life span in individuals with MS
compared with the general population.
In this study, we investigated the relationship
between tobacco smoking and the life span and mor-
tality rates in a large cohort of MS patients and exam-
ined whether smoking can explain the reported
increased mortality seen in MS populations.
METHOD
Settings and study design
We studied participants in the Nottingham University
Hospitals MS Clinics database during the period
1994–2013. This is a major regional referral centre
for MS in East Midlands Counties of England. Our
methods and cohort characteristics have been
described in detail elsewhere.11 Brieﬂy, the centre
covers more than 3000 MS patients. Among all the
patients who are regularly seen in these MS specia-
lised clinics, 1032 patients were routinely followed
up and details of the disease clinical course, disability
scores, date of diagnosis and disease onset, treatment,
comorbid conditions, etc., were systematically docu-
mented. Our ﬁnal study population consisted of
patients with clinically deﬁnite MS according to the
McDonald and/or Poser criteria14 15 made by an MS
specialist neurologist.
Measurements
Clinical data and smoking history
Smoking history was obtained during patients’
ﬁrst clinic visit at the time of disease onset and/or
diagnosis, and patients were grouped as non-
smokers, ex-smokers or current smokers. In the
majority of the cases, smoking history was
updated and recorded more than once after the
disease onset during regular clinic follow-ups. For
this study, we used the latest smoking status
recorded in the database. The date of the ﬁrst
manifestation of the disease, date of diagnosis,
duration of exposure to disease-modifying treat-
ments (DMTs), latest Expanded Disability Status
Scale (EDSS) score16 recorded in clinic, sex and
initial clinical course of the disease (relapsing-
remitting (RR) vs primary-progressive (PP)) were
used in this report. We also calculated the global
MS severity score (MSSS), which integrates EDSS
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score and disease duration according to the guidelines pub-
lished by Roxburgh et al.17
Vital status and cause of death
Vital status of patients was monitored and the exact date of
death was obtained through linkage of the MS cohort to
National Health Service (NHS) vital statistics as of December
2012 (index date). For the cause of death, both medical records
and death certiﬁcates were used. Causes of death were cate-
gorised into MS-related (death due to MS disability such as
bronchopneumonia, pulmonary embolism, sepsis) and
non-MS-related deaths (eg, cancers, suicides, cardiovascular
diseases).18
Statistical analysis
Patient data from the time of entry into the database until either
death or the index date (December 2012), whichever occurred
ﬁrst, were included. Time at risk and death rates were calculated
per 1000 person-years. CIs for median survival age could not
be estimated as less than half the patients have died by
December 2012. Since the distribution was reasonably normal,
we used parametric measures and calculated mean survival from
birth and after MS onset. Smoking-speciﬁc rates were calculated
using Cox proportional hazard regression models controlled for
sex, onset age, use of DMTs (in a binary group of ≥1 year or
<1 year) and initial clinical course of MS (RR vs PP). By basing
the survival time on age, we made sure that the effects of age as
one of the most important factors in progression have been
properly controlled for. The ﬁnal model was checked for pro-
portionality assumption based on the Schoenfeld residuals, and
stratiﬁcation was made if necessary to hold the proportionality
assumption. We also calculated standardised mortality ratios
(SMRs) and performed external comparison of our mortality to
both the UK general population data and mortality rates of male
British doctors cohort.19 The male British doctors study con-
tains the mortality rates stratiﬁed by age and smoking status.
The smoking-speciﬁc mortality rates from this cohort enabled
us to measure the excess mortality in different smoking categor-
ies in male patients with MS. SMR was calculated by dividing
the observed number of deaths in the cohort by the number of
deaths expected from the general population for each sex and
age band stratum (20–24, 25–29, …, up to >85 years). Since all
the deaths (n=80) in our cohort occurred in the 2001–2012 cal-
endar period, we used 2006 UK mortality rates as the corre-
sponding reference rates, obtained from the UK Ofﬁce for
National Statistics for each sex and age group.20 All statistical
analyses were performed with Stata V.11.2.21
FINDINGS
Our cohort consisted of 923 (89% of 1032 subjects) individuals
with clinically deﬁnite MS and full data for analysis. In total,
70% of the subjects were female, 11% had PP MS at disease
onset and 89% had RR MS at onset. Of those RR MS subjects,
40% had transited to secondary progressive (SP) MS. In general,
deceased patients in our cohort had signiﬁcantly older onset
age, longer disease duration and higher MSSS and EDSS scores
compared with survivors. Also, 58% of the deceased patients
and 30% of survivors were male; 45% of the survivors had
received DMTs for 1 year or longer compared with only 16% of
deceased subjects. Average treatment duration was 4.73 (SD
±3.36) years for the whole cohort. Despite the decrease in the
prevalence of ever-smoking in the UK general population,22
there was an increase of approximately 12% in the proportion
of ever smokers in our cohort in 2000–2010 compared with
that of the proportion before 1990 (data not shown) in the MS
cohort. Table 1 shows the baseline demographic and
MS-speciﬁc characteristics of our cohort by vital status at our
index date.
Length of follow-up and smoking status
The 923 patients contributed a total of 18 717 person-years of
data. There were 80 deaths recorded in our cohort, representing
a mortality rate of 4.35 (95% CI 3.43 to 5.34) per 1000
person-years. This rate was higher in males (8.68, 95% CI 6.52
to 11.56) than in females (2.47, 95% CI 1.76 to 3.48). When
compared with the frequency of 50% in the whole cohort, 67%
of the deceased subjects were ever smokers (n=54). All nine
patients with RR MS who died were ever smokers compared
with 44% of PP MS and almost 68% of SP MS patients. Of
patients with relapse onset MS, 37% among those who were
still alive and 67% in the deceased group had transited to SP
MS.
Survival rates and role of smoking
Estimated mean survival was 76.8 years (95% CI 74.6 to 79)
for the whole cohort. Estimated mean survival was 81 (95% CI
78 to 83.6) years in non-smokers, 78.4 (95% CI 75.2 to 81.5)
years in ex-smokers and 71.5 (95% CI 68.8 to 74.2) in current
smokers (Log-rank test, χ2 (2)=20.12, p<0.001) (ﬁgure 1A,B).
The estimated mean survival was not different between RR MS
and PP MS (Log-rank test, χ2 (1)=0.38, p=0.53).
While controlling for onset age, DMT and disease initial
course and stratifying for sex (to maintain the proportionality
assumption), current smokers but not ex-smokers were at higher
risk of death, with a HR relative to never smokers of 2.70 (95%
CI 1.59 to 4.58; p<0.001) and 1.30 (95% CI 0.72 to 2.32;
p=0.37), respectively. Exposure to DMT for 1 year or longer
was associated with 50% (HR 0.50, 95% CI 0.26 to 0.93;
p=0.03) reduction in the risk of death, and each year increase
in age at the onset of MS was associated with 4% (95% CI 0.94
to 0.98; p=0.004) decrease in the risk of death. Risk of death
was not signiﬁcantly increased in PP MS patients compared with
RR MS (HR 1.16, 95% CI 0.65 to 1.06; p=0.65).
Since both EDSS and year of birth are signiﬁcant contributory
factors in the risk of death, they were added to the model to
check whether the effect size of smoking remains signiﬁcant.
Table 1 General demographic characteristics of the cohort by vital







Age (mean (SD)) 56 (±12) 51 (±10) =0.001
Sex (female %) 34 (42%) 610 (72%) <0.001
Last recorded EDSS
(median (range))
7.5 (6.5–8.0) 5.5 (3.0–6.5) <0.001
MSSS (mean (SD)) 7.9 (±2.23) 5.34 (±2.59) <0.001
Age at the onset (mean (SD)) 35 (±10.67) 32 (±9.74) =0.02
Disease duration (median
(range))
18 (10–26) 15 (9–23) =0.06
Type of MS <0.001
Relapsing-remitting 9 (11%) 445 (52%)
Primary-progressive 16 (20%) 87 (10%)
Secondary-progressive 55 (69%) 311 (37%)
DMT ≥1 year 13 (16%) 384 (45%) <0.001
DMT, disease-modifying treatment; EDSS, expanded disability status scale; MSSS,
multiple sclerosis severity score.
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When the latest EDSS score and year of birth were added to the
model, the effect size of smoking increased to 2.92 (95% CI
1.50 to 5.71; p=0.002) in current smokers and 1.62 (95% CI
0.79 to 3.34; p=0.18) in ex-smokers compared with non-
smokers and exposure to DMT for at least a year was associated
with 68% reduction in the risk of death (HR 0.32, 95% CI
0.14 to 0.72; p=0.006).
Limiting our survival analysis to those who died from
MS-related causes, current smokers were still at higher risk for
death, with a HR of 2.93 (95% CI 1.48 to 5.76; p<0.001) rela-
tive to non-smokers. Among ex-smokers, the HR was 1.18
(95% CI 0.53 to 2.61; p=0.67).
Disability status and cause of death
Latest recorded disability status was signiﬁcantly higher in
deceased subjects relative to survivors as measured by EDSS
score and MSSS. We could not obtain causes of death in two of
the decedents. Cause of death was MS-related in 60% of cases
(table 2), with bronchopneumonia accounting for the majority
of MS-related deaths. Cancer (17.5%) was the commonest
non-MS-related cause, and lung cancer the dominant cancer (six
deaths). Deaths from cardiovascular diseases (11 cases), suicide
(1 case), motor neuron disease (1 case), kidney failure (2 cases),
liver cirrhosis and gastrointestinal infarction were also recorded.
Standardised mortality ratio
All-cause mortality in MS patients was signiﬁcantly higher than
expected in age-matched and sex-matched general population,
the SMR being 2.41 (95% CI 1.95 to 2.96; p<0.001) for
males, 1.80 (95% CI 1.40 to 2.30; p<0.001) for females and
1.99 (95% CI 1.70 to 2.33; p<0.001) for both sexes combined.
The all-cause SMR in current smokers was 3.83 (95% CI 2.71
to 5.42; p<0.001) and in ex-smokers 1.96 (95% CI 1.27 to
3.0; p<0.001); among never smokers SMR was 1.27 (95% CI
0.87 to 1.86; p=0.07) compared with the rates in the general
population.
The non-smokers and ex-smokers with MS did not have sig-
niﬁcant excess mortality compared with their age-matched and
smoking status-matched counterparts in the British doctors
cohort study (SMR 1.12, 95% CI 0.63 to 1.97 and SMR 0.54,
95% CI 0.26 to 1.14, respectively). However, the SMR for
current smokers with MS compared with current smokers
without MS was 1.84 (95% CI 1.24 to 2.72) (table 3).
DISCUSSION
In this MS population, current smoking was associated with
more than 2.5-fold increased risk of death. Current smokers
with MS had a reduction of about 10 years in their life expect-
ancy relative to non-smokers with MS. When compared with
the general population, increased mortality in this cohort as
measured by SMR was seen in current and ex-smokers, but our
results indicated that mortality may not be increased in non-
smokers with MS. The risk of death in ex-smokers was consider-
ably lower than that in current smokers. When the mortality in
Table 3 Standardised mortality ratio for all-cause mortality
compared with the UK general population and male British doctors
cohort
SMR (general population) SMR (male British doctors)
Overall 1.99 (1.70 to 2.33) –
Male 2.41 (1.95 to 2.96) –
Female 1.80 (1.40 to 2.30) –
Non-smokers 1.27 (0.87 to 1.86) 1.12 (0.63 to 1.97)
Ex-smokers 1.96 (1.27 to 3.0) 0.54 (0.26 to 1.14)
Current smokers 3.83 (2.71 to 5.42) 1.84 (1.24 to 2.72)
SMR, standardised mortality ratio and CIs (95%).
Figure 1 Cox proportional hazard regression graph showing survival
from birth (A) by lifelong smoking status and (B) latest smoking status.
Table 2 Summaries of causes of death, onset age, disability score
and disease severity by patients’ lifelong smoking status
Cause of
death
















32 36 8 15 33 8.5
Pneumonia 21 8 9 8.5
Sepsis 4 8 2 8
Other or not
specified
7 8 4 8
Cancer 10 33 6 4 27 7
Cardiovascular 7 38 6 4 36.5 7
Other 2 27.5 7 4 38 8
EDSS, expanded disability status scale; MS, multiple sclerosis.
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each smoking category in our patients was compared with the
mortality in smoking categories in the British doctors cohort
study, we found that current smokers with MS have increased
mortality risk (84%) compared with their counterparts without
MS. Interestingly, non-smokers and ex-smokers with and
without MS had similar mortality rates compared with non-
smokers and ex-smokers without MS. These data are consistent
with our recent ﬁndings of the negative impact of current
smoking on disability and severity of the disease in MS.11
The estimated survival age of 77 for our MS population in
the present study is comparable to the ﬁndings from a recent
study in the UK23 and from Canada.3 Our patients were two
times more likely to die prematurely compared with their age-
matched and sex-matched counterparts in the UK general popu-
lation. Although SMRs cannot be comfortably compared due to
differences in distribution of the standardisation variables (age
and sex) across the study populations, our presented SMR here
is lower, though still comparable, with those reported previ-
ously.1 3 18 24 25 The overall reported SMR here compared with
the UK general population is higher than the reported SMR of
1.3 in a French study.26 Apart from methodological variations,
treatment and access to healthcare resources may further explain
the lower SMR in the cohort presented here. While 57% of the
patients in the French study and 42% of our cohort have been
exposed to treatment, the majority of the patients in British
Columbia3 were never exposed to treatment and the follow-up
time in the Danish study1 predated treatment. This may explain
some of the differences seen between our reported SMR here
and those reported previously.
In our cohort, the risk of death was halved for patients who
had been exposed to at least 1 year of DMTs. However, the
assignment of DMTs to a selective population of patients may
introduce bias to the results. Our results presented here are in
line with the ﬁndings from the long-term follow-up of patients
participating in the original interferon-β clinical trial, which has
shown that exposure to treatment may decrease risk of prema-
ture death.27 Also, follow-up of patients in Taiwan28 showed a
reduced risk of mortality in patients with history of exposure to
DMTs. The mechanism by which DMTs can reduce the risk of
premature death is unclear. We could not observe any inﬂuence
of DMTs in reducing the risk of reaching two EDSS score mile-
stones 4 and 6 in our cohort (data not shown). One possible
explanation is the ability of interferon to reduce the risk of
infection.29 Nevertheless, the potential inﬂuence of treatment
intervention in MS on mortality deserves further investigation.
Mortality is a major component of population change and
many health conditions and interventions reﬂect on mortality
rates. This, along with unique characteristics such as exact date
and time, makes mortality a relevant outcome in studies of MS. In
the UK, it has been shown that current smokers with MS have
6.7-fold (95% CI 4.16 to 10.87) increased mortality rate com-
pared with the sex-matched and age-matched counterparts
without MS while the rate for never smokers was 2.85 (95% CI
1.86 to 4.37).30 Our results conﬁrm a higher mortality rate in
current smokers versus non-smokers (HR 2.7, 95% CI 1.59 to
4.58; p<0.001).
Our study had some limitations. First, it is possible that our
study has missed some of the patients with very severe disease
who have died before the data collection. Second, our calculated
SMR, which used reference mortality rates from the male
British doctors study, were limited to the male patients while
70% of our cohort were female. In addition, the reported mor-
tality rates in that study of male British doctors, which is a his-
toric cohort (1951–2001), are higher from the more recent
ones. Hence, it is likely that the SMR versus male doctors sub-
stantially underestimates the excess mortality for the MS cohort
for the non-smoker and current smoker groups. We cannot rule
out the possibility of reverse causality bias (or the healthy
smoker bias31) when ex-smokers probably quit smoking because
of the worsening of their MS. As a consequence, the effect size
of current smoking versus ex-smokers may be biased by selec-
tion of those current smokers who have experienced fewer dis-
abilities, are still alive and continued to smoke.
To our knowledge, this is the ﬁrst study investigating smoking
as a factor inﬂuencing life expectancy in patients with MS. Here
we have presented data from a cohort of MS patients in the UK,
but the relevance of this study is likely to be worldwide. As
shown here, smoking is a signiﬁcant risk factor for all-cause and
MS-related death, causing almost 10 years loss of life expectancy
in patients with MS. In contrast, our data suggest that mortality
may not be increased substantially in non-smokers with MS rela-
tive to the general population and non-smokers in the male
British doctors study.
In the general population, tobacco smoking reduces life
expectancy mainly by increasing the risk of cancer22 and cardio-
vascular diseases.32 In MS, vascular comorbidities were shown
to associate with a more severe disease evolution,33 which can
potentially mediate the effect of smoking on mortality in MS.
However, our risk estimates remained almost unchanged when
only those who died from MS-related causes were analysed. In
addition, we did not observe any increased mortality rate due to
cancer and cardiovascular diseases compared with the UK
general population (SMR due to cancer 0.61, 95% CI 0.37 to
1.01; and SMR due to cardiovascular diseases 0.83, 95% CI
0.46 to 1.50). The exact mechanism in which smoking increases
the risk of premature death in MS deserves further investigation.
One possible explanation is the increased risk of mortality due
to pneumonia, for which smoking has been shown to be a sig-
niﬁcant risk factor.34 35 In our cohort, the number of ever
smokers who died from pneumonia was more than two times
higher than never smokers (n=21 vs n=9).
On the basis of our ﬁndings, there is a strong association
between tobacco smoking and premature mortality in patients
with MS. The evidence of reduced risk of death among former
smokers compared with current smokers calls for effective cessa-
tion strategies. Our data suggest that reduction in prevalence of
tobacco smoking in people with MS is one factor that can
potentially decrease the excess mortality rates seen in MS
patients. Tools and information to help smokers with MS stop
smoking and non-smokers to never start smoking should be pro-
vided to all patients with MS.
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